Dr. Naomi Sacks, BRLS Vice President in our Pharmaceutical Commercialization practice, is a co-author of a study recently published in JAC-Antimicrobial Research. Dr…. read more
We are pleased to announce that Amanda Burns, MSPH, DABT, recently joined ToxStrategies as a Principal Scientist in our Causation Analysis practice. Amanda… read more
Understanding the Full Picture of Chemical and Environmental Exposures Regulators, industry, and the public are increasingly focused on the combined effects of multiple… read more
EpidStrategies’ scientists Mina Suh, Naimisha Movva, and Sue Pastula have authored a new systematic literature review in Cancer Treatment and Research Communications. This… read more
Dr. Naomi Sacks, Vice President, BlueRidge Life Sciences’ Pharmaceutical Commercialization division, is attending the annual meeting of ISPOR (The Professional Society for Health Economics… read more
In the United States, the most common childhood central nervous system cancer is pediatric low-grade glioma, but there are no standardized coding definitions… read more
BlueRidge Life Sciences is at the annual meeting of ISPOR (The Professional Society for Health Economics and Outcomes Research), held this year in… read more
BlueRidge Life Sciences Pharmaceutical Commercialization’s Dr. Naomi Sacks’s work published in Obesity Science & Practice on behalf of The Obesity Society was recently… read more
ToxStrategies and EpidStrategies are pleased to announce the promotion of 12 of our scientists, epidemiologists and engineers. We are proud to have them… read more
Dr. Naomi Sacks, HEORStrategies Vice President, is a co-author on a recently published study, “Impact of Demographics and Insurance Coverage on Schizophrenia Treatment… read more